Stay connected! Share and follow:

Leukaemia CARE Careline

We're here to talk | 24-hours a day

08088 010 444

FREE from landlines & most major mobile networks

07
Jul
AWMSG recommends brentuximab vedotin

written by

Leukaemia Care, Charity

  • PIXABAY-5042016-cure-1006811_1920

Earlier this month (01/07/2015) the All Wales Medicines Strategy Group (AWMSG) recommended the use of brentuximab vedotin within NHS Wales. Brentuximab is marketed by Takeda as Adcetris®.

This recommendation has taken account of the views of clinical experts, patients and patient representatives (including Leukaemia CARE).

The AWMSG have recommended brentuximab vedotin for “restricted use within NHS Wales for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma following autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option. Brentuximab vedotin is not recommended for use within NHS Wales for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL).”

This means that within three months of Ministerial approval (which occurred on 26/06/2015), brentuximab vedotin will be routinely available within NHS Wales for the recommended indication.

View a copy of the AWMSG’s recommendation here.

Monica Izmajlowicz, Chief Executive of Leukaemia CARE said: “This decision by the AWMSG to approve brentuximab vedotin is extremely positive news for Hodgkin lymphoma patients throughout Wales. This treatment offers hope to patients where limited effective alternatives were previously available.”

If you are affected by these changes and would like to speak to somebody about it, please call our 24-hour CARE Line on 08088 010 444.